- Home
- IDYA vs WULF Comparison
IDYA vs WULF Comparison
Compare IDYA & WULF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- WULF
- Stock Information
- Founded
- IDYA 2015
- WULF 1952
- Country
- IDYA United States
- WULF United States
- Employees
- IDYA N/A
- WULF N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- WULF EDP Services
- Sector
- IDYA Health Care
- WULF Technology
- Exchange
- IDYA Nasdaq
- WULF Nasdaq
- Market Cap
- IDYA 1.9B
- WULF 1.9B
- IPO Year
- IDYA 2019
- WULF 1995
- Fundamental
- Price
- IDYA $24.27
- WULF $5.10
- Analyst Decision
- IDYA Strong Buy
- WULF Strong Buy
- Analyst Count
- IDYA 13
- WULF 8
- Target Price
- IDYA $50.82
- WULF $8.44
- AVG Volume (30 Days)
- IDYA 1.0M
- WULF 57.6M
- Earning Date
- IDYA 08-05-2025
- WULF 08-08-2025
- Dividend Yield
- IDYA N/A
- WULF N/A
- EPS Growth
- IDYA N/A
- WULF N/A
- EPS
- IDYA N/A
- WULF N/A
- Revenue
- IDYA $7,000,000.00
- WULF $132,023,000.00
- Revenue This Year
- IDYA $115.83
- WULF $45.98
- Revenue Next Year
- IDYA $252.50
- WULF $83.67
- P/E Ratio
- IDYA N/A
- WULF N/A
- Revenue Growth
- IDYA N/A
- WULF 31.85
- 52 Week Low
- IDYA $13.45
- WULF $2.06
- 52 Week High
- IDYA $44.42
- WULF $9.30
- Technical
- Relative Strength Index (RSI)
- IDYA 63.79
- WULF 55.80
- Support Level
- IDYA $21.33
- WULF $4.84
- Resistance Level
- IDYA $25.54
- WULF $5.45
- Average True Range (ATR)
- IDYA 1.00
- WULF 0.37
- MACD
- IDYA 0.20
- WULF -0.02
- Stochastic Oscillator
- IDYA 70.60
- WULF 41.63
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About WULF TeraWulf Inc.
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.